Recent studies reveal that the absolute risk reductions from statin treatment are modest when compared to relative risk reductions. Significant differences in cardiovascular benefits exist between trials conducted before and after 2004, raising questions about statin prescribing. For patients with limited life expectancy or adverse effects, considering the withholding of statin therapy may be beneficial, especially when addressing underlying causes like insulin resistance.
